News: GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,392.00GBp
19 Dec 2014
Price Change (% chg)

13.50p (+0.98%)
Prev Close
1,378.50p
Open
1,388.50p
Day's High
1,395.50p
Day's Low
1,362.00p
Volume
16,400,426
Avg. Vol
9,804,746
52-wk High
1,709.00p
52-wk Low
1,296.50p

Search Stocks
Select another date:

Fri, Dec 19 2014

Photo

GSK Ebola vaccine trial seen moving to wider phase in February

GENEVA - Trials of GlaxoSmithKline's experimental Ebola vaccine are likely to move to a second phase in February, later than previously suggested, after a meeting of national regulators said they needed more information.

GSK Ebola vaccine trial seen moving to wider phase in February

GENEVA, Dec 19 - Trials of GlaxoSmithKline's experimental Ebola vaccine are likely to move to a second phase in February, later than previously suggested, after a meeting of national regulators said they needed more information.

UPDATE 1-New GSK shingles vaccine may challenge Merck after strong test data

* GSK vaccine cuts risk of shingles by 97.2 pct in over 50s

GSK shareholders approve asset swap deal with Novartis

LONDON, Dec 18 - Shareholders in British drugmaker GlaxoSmithKline have approved a planned deal with Switzerland's Novartis, which will see the two pharmaceutical groups trade more than $20 billion of assets.

GlaxoSmithKline shingles vaccine hits goal in major study

LONDON, Dec 18 - An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its overall healthcare business.

Fitch Affirms GlaxoSmithKline PLC at 'A+'; Revises Outlook to Negative

(The following statement was released by the rating agency) LONDON, December 17 (Fitch) Fitch Ratings has affirmed UK-based pharmaceuticals company GlaxoSmithKline PLC's (GSK) Long-term Issuer Default Rating (IDR) and senior unsecured rating at 'A+'. The Outlook has been revised to Negative from Stable. Fitch has also affirmed the senior unsecured rating of 'A+' for the debt issued under GlaxoSmithKline Capital PLC. The Negative Outlook encapsulates Fitch's expectation of increasing financia

Antibiotic developer Cempra's CEO says not looking for a buyer

- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers.

BRIEF-GSK files regulatory submission for variation to marketing authorisation for Ambrisentan

* GSK press release: GSK announces EU regulatory submission seeking extended indication for Ambrisentan (Volibris) in pulmonary arterial hypertension

One shot or two? Many questions unresolved in Ebola vaccine race

* Debate over "prime-boost" vaccination as epidemic evolves

BRIEF-Aspen Pharmacare director Abbas Hussain resigns

* Abbas Hussain has confirmed that he intends to tender his resignation as a director of company with effect from Feb. 1 2015

Select another date:

Press Releases

Search Stocks